

deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent.

By order of the Commission.  
 Issued: February 28, 2019.

**Lisa Barton,**  
*Secretary to the Commission.*  
 [FR Doc. 2019-03987 Filed 3-5-19; 8:45 am]  
**BILLING CODE 7020-02-P**

**DEPARTMENT OF JUSTICE**

**Antitrust Division**

**Notice Pursuant to the National Cooperative Research and Production Act of 1993—X12 Incorporated**

Notice is hereby given that, on February 11, 2019, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), X12 Incorporated (“X12”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the name and principal place of business of the standards development organization and (2) the nature and scope of its standards development activities. The notifications were filed for the purpose of invoking the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to Section 6(b) of the Act, the name and principal place of business of the standards development organization is: X12 Incorporated, McClean, VA. The nature and scope of X12’s standards development activities are: The development and maintenance of cross industry e-commerce standards that improve business process interoperability and facilitate business information exchange supporting the

finance, government, supply chain, transportation and insurance industries and associated business partners.

**Suzanne Morris,**  
*Chief, Premerger and Division Statistics Unit, Antitrust Division.*  
 [FR Doc. 2019-04010 Filed 3-5-19; 8:45 am]  
**BILLING CODE 4410-11-P**

**DEPARTMENT OF JUSTICE**

**Antitrust Division**

**Notice Pursuant to the National Cooperative Research and Production Act of 1993—HEI Industry Group**

Notice is hereby given that, on January 28, 2019, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), HEI Industry Group (“HIG”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties to the venture and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to Section 6(b) of the Act, the identity of the parties to the venture are: Chevron North America Exploration and Production Company, a division of Chevron U.S.A. Inc., Houston, TX; ConocoPhillips Company, Houston, TX; Exxon Mobil Corporation, Irving, TX; Halliburton Energy Services, Inc., Houston, TX; Noble Energy, Inc., Houston, TX; SWEPI LP (SWEPI), Houston, TX; Schlumberger Technology Corporation, Houston, TX; BHP, Houston, TX; Statoil Gulf Services LLC, Houston, TX; and Schlumberger Limited, N.V., Houston, TX. The general area of HIG’s planned activity is to commence a joint industry-government research initiative entitled HEI’s Energy Research Program to (1) evaluate the existing health and exposure literature related to potential impacts from onshore oil and natural gas operations; and possibly (2) conduct a study to assess potential exposures from those

operations. The industry sponsors have created the HEI Industry Group (HIG) to facilitate coordinated input to HEI. HEI is a nonprofit organization chartered in 1980 as an independent research institute to provide high-quality, impartial, and relevant science on the health effects of air pollution. The HEI-managed program represents a first-of-its-kind, comprehensive collaboration between the oil and gas industry and government to assess exposure to chemical stressors associated with onshore unconventional oil and natural gas operations. Part 1 of the research program will last for approximately one year and will evaluate the existing health and exposure literature as well as conduct workshops to inform the literature reviews and frame research needs. Part 2 (an exposure study) is being considered and will be informed by the results of the Part 1 literature review. If Part 2 goes forward, future studies will be considered as warranted by the Part 2 results.

**Suzanne Morris,**  
*Chief, Premerger and Division Statistics Unit, Antitrust Division.*  
 [FR Doc. 2019-04009 Filed 3-5-19; 8:45 am]  
**BILLING CODE 4410-11-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Importer of Controlled Substances Registration**

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and been granted registration by-the Drug Enforcement Administration (DEA) as an importer of schedule I controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as an importer of scheduled I controlled substances. Information on the previously published notice is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for this notice.

Company	FR Docket	Published
Agilent Technologies .....	83 FR 66751 .....	December 27, 2018.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823, 952(a) and

958(a) and determined that the registration of the listed registrant to import the applicable basic classes of

schedule I controlled substances is consistent with the public interest and with United States obligations under

international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I controlled substances to the above listed company.

Dated: February 22, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019-04026 Filed 3-5-19; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Bulk Manufacturer of Controlled Substances Application: Patheon Pharmaceuticals, Inc.**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 5, 2019. Such persons may also file a written request for a

hearing on the application on or before April 5, 2019.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on December 24, 2018, Patheon Pharmaceuticals, Inc., 2110 E Galbraith Road, Cincinnati, Ohio 45237, has re-applied to be registered as a bulk manufacturer of the Schedule I controlled substance Gamma Hydroxybutyric Acid (2010), a basic class of controlled substance.

The Gamma Hydroxybutyric Acid will be produced during the process of converting gamma-butyrolactone (GBL)

into a new product for development. The company plans to manufacture the above listed controlled substance as Active Pharmaceutical Ingredient (API) that will be further synthesized into dosage forms of a new product. No other activities for this drug code are authorized for this registration.

Dated: February 18, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019-04029 Filed 3-5-19; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Bulk Manufacturer of Controlled Substances Registration**

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and has been granted a registration by the Drug Enforcement Administration (DEA) as a bulk manufacturer of various classes of schedule I and II controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as a bulk manufacturer of various basic classes of controlled substances. Information on the previously published notice is listed in the table below. No comments or objections were submitted for this notice.

Company	FR Docket	Published
Cambrex Charles City .....	83 FR 49579 .....	October 2, 2018.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of this registrant to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing their physical security systems, verifying their compliance with state and local laws, and reviewing their background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a

registration as a bulk manufacturer to the above listed company.

Dated: February 22, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019-04027 Filed 3-5-19; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Bulk Manufacturer of Controlled Substances Registration**

**ACTION:** Notice of registration.

**SUMMARY:** Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as bulk manufacturers of schedule I or schedule II controlled substances.

**SUPPLEMENTARY INFORMATION:** The companies listed below applied to be registered as bulk manufacturers of schedule I or schedule II controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted for these notices.